• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by BeiGene Ltd.

    12/4/24 4:05:33 PM ET
    $BGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BGNE alert in real time by email
    SC 13D/A 1 p24-3466sc13da.htm BEIGENE, LTD.
    SECURITIES AND EXCHANGE COMMISSION  
    Washington, D.C. 20549  
       
    SCHEDULE 13D/A
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 5)*
     

    BeiGene, Ltd.

    (Name of Issuer)
     

    Ordinary shares, par value $0.0001 per share

    (Title of Class of Securities)
     

    07725L102

    (CUSIP Number)
     

    Richard A. Hornung

    HHLR Advisors, Ltd.

    Office #122, Windward 3 Building, Regatta Office Park

    West Bay Road, Grand Cayman

    Cayman Islands, KY1-9006

     

    With a copy to:

     

    Eleazer N. Klein, Esq.

    Adriana F. Schwartz, Esq.

    Schulte Roth & Zabel LLP

    919 Third Avenue

    New York, NY 10022

    (212) 756-2000

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)
     

    December 2, 2024

    (Date of Event Which Requires Filing of This Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box. [ ]

     

    (Page 1 of 5 Pages)

    ______________________________

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

      

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 07725L102SCHEDULE 13D/APage 2 of 5 Pages

     

    1

    NAME OF REPORTING PERSON

    HHLR Advisors, Ltd.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    AF (See Item 3)

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Cayman Islands

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    7

    SOLE VOTING POWER

    -0-

    8

    SHARED VOTING POWER

    125,045,741 Ordinary Shares*

    9

    SOLE DISPOSITIVE POWER

    -0-

    10

    SHARED DISPOSITIVE POWER

    125,045,741 Ordinary Shares*

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    125,045,741 Ordinary Shares*

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    9.0%

    14

    TYPE OF REPORTING PERSON

    IA

             

     

    * Consists of (i) 111,597,423 ordinary shares held by a fund managed by HHLR (as defined below), of which 36,011,300 ordinary shares are held in the form of 2,770,100 ADSs and (ii) 13,448,318 ordinary shares held by a fund managed by HIM (as defined below), of which 13,445,978 ordinary shares are held in the form of 1,034,306 ADSs. HHLR and HIM are under common control and share certain policies, personnel and resources.

     

     

    CUSIP No. 07725L102SCHEDULE 13D/APage 3 of 5 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Hillhouse Investment Management, Ltd.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    AF (See Item 3)

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Cayman Islands

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    7

    SOLE VOTING POWER

    -0-

    8

    SHARED VOTING POWER

    125,045,741 Ordinary Shares*

    9

    SOLE DISPOSITIVE POWER

    -0-

    10

    SHARED DISPOSITIVE POWER

    125,045,741 Ordinary Shares*

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    125,045,741 Ordinary Shares*

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    9.0%

    14

    TYPE OF REPORTING PERSON

    IA

             

     

    * Consists of (i) 111,597,423 ordinary shares held by a fund managed by HHLR, of which 36,011,300 ordinary shares are held in the form of 2,770,100 ADSs and (ii) 13,448,318 ordinary shares held by a fund managed by HIM, of which 13,445,978 ordinary shares are held in the form of 1,034,306 ADSs. HHLR and HIM are under common control and share certain policies, personnel and resources.

     

     

    CUSIP No. 07725L102SCHEDULE 13D/APage 4 of 5 Pages

     

    This Amendment No. 5 (“Amendment No. 5”) amends the statement on Schedule 13D previously filed by the Reporting Persons with the Securities and Exchange Commission (the “SEC”) (as previously filed and amended and amended further hereby, the “Schedule 13D”) with respect to the ordinary shares, par value $0.0001 per share (the “Ordinary Shares”) of BeiGene, Ltd., an exempted Cayman Islands company (the “Issuer”). Capitalized terms used herein and not otherwise defined in this Amendment No. 5 have the meanings set forth in the Schedule 13D. This Amendment No. 5 amends Items 5 (a)-(c) as set forth below.

     

    Item 5. Interest in Securities of the Issuer
       
    Items 5 (a)-(c) of the Schedule 13D are hereby amended and restated as follows:
     
    (a) See rows (11) and (13) of the cover pages to this Schedule 13D/A for the aggregate number of Ordinary Shares and percentages of the Ordinary Shares beneficially owned by each Reporting Person.  The percentage used in this Schedule 13D/A is calculated based upon 1,386,034,320 Ordinary Shares outstanding as of November 1, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024, filed with the Securities and Exchange Commission on November 12, 2024.
       
    (b) See rows (7) through (10) of the cover pages to this Schedule 13D for the number of Ordinary Shares as to which each Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition.
       
    (c)

    On December 2, 2024, HHLR Fund sold 1,372,500 ADSs pursuant to a block trade with Goldman Sachs & Co. LLC at a price of $200 per ADS.

       

     

     

    CUSIP No. 07725L102SCHEDULE 13D/APage 5 of 5 Pages

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this Schedule 13D/A is true, complete and correct.

     

    Date: December 4, 2024

     

      HHLR Advisors, LTD.
       
       
       
     

    /s/ Audrey Woon

     

    Name: Audrey Woon

    Title: Chief Compliance Officer

     

      HillHOUSE INVESTMENT MANAGEMENT, LTD.
       
       
       
     

    /s/ Audrey Woon

     

    Name: Audrey Woon

    Title: Chief Compliance Officer

     

     

    Get the next $BGNE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BGNE

    DatePrice TargetRatingAnalyst
    12/3/2024$300.00Overweight
    Morgan Stanley
    9/18/2024$288.00Mkt Outperform
    JMP Securities
    2/6/2024$185.00Overweight
    JP Morgan
    9/12/2023$259.00Outperform
    Macquarie
    8/17/2023$287.00Buy
    Jefferies
    7/17/2023$275.00Buy
    Citigroup
    6/30/2023$335.00 → $196.00Outperform → Mkt Perform
    Bernstein
    1/12/2023$308.00Buy
    Daiwa Securities
    More analyst ratings